Top ASH 2025 updates in AML: redefining frontline therapy, menin inhibition, venetoclax-based triplets, & emerging immunotherapies

This VJHemOnc podcast highlights key acute myeloid leukemia (AML) updates from ASH 2025, spanning frontline therapy, molecularly targeted approaches, venetoclax-based combinations, and emerging immunotherapies. Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the Phase II PARADIGM study (NCT04801797) comparing azacitidine plus venetoclax with intensive chemotherapy, alongside updated KOMET-007 trial (NCT05735184) results of ziftomenib plus azacitidine and venetoclax in NPM1-mutated or KMT2A-rearranged AML. Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, reviews the Phase I/II VICEROY study (NCT05520567) of venetoclax, azacitidine, and gilteritinib in newly diagnosed FLT3-mutated AML ineligible for intensive therapy. Naval Daver, MD, MD Anderson Cancer Center, Houston, TX, presents a Phase Ib/II trial (NCT04086264) of pivekimab sunirine plus azacitidine and venetoclax in unfit newly diagnosed AML. Wei-Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, shares results of the Phase II SAVE study (NCT05360160) exploring an all-oral revumenib, decitabine/cedazuridine, and venetoclax regimen, while Mohammad Maher Abdul-Hay, MD, NYU Langone Health, New York City, NY, discusses early data from the Phase I trial (NCT05143996) of the FLT3 x CD3 bispecific CLN-049 in relapsed or refractory AML.